A large new population study of men over 45 indicates insulin resistance may be an important risk factor for the development ...

Edwards Lifesciences (NYSE:EW) today announced its plans for significant growth as a purely structural heart company in 2025.

Insulin resistance can increase the risk of aortic stenosis -- a common heart valve disease, in men over the age of 45, finds ...

In the CONDUCT-TAVI study, the use of a self-expanding valve was not associated with an increased risk of pacemaker.

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/90.BMDkfsfZ.js ...

Anteris Technologies Global Corp. aims to raise $75 million in an IPO for aortic stenosis treatment development in a growing ...

Edwards Lifesciences Corporation (NYSE: EW) will discuss the company’s focused strategy for long-term sustainable growth, ...

A recent study has revealed a strong link between insulin resistance and an increased risk of aortic stenosis (AS), a ...

Abbott has taken a step forward in the development of a new addition to its structural heart portfolio, completing the first ...

Insulin resistance associated with prediabetes appears to raise a person’s risk of a common and serious heart valve ...

FY24 consensus $5.83B. “It is an exciting day for Edwards as we share our vision for 2025 and how our talented team and focus in structural ...

Edwards Lifesciences (EW) reaffirmed original 2024 total company constant currency sales growth guidance of 8% to 10%. The company is ...